慢性阻塞性肺疾病患者呼出气冷凝液中白介素9水平变化分析

发布时间：2018-09-01 13:50

【摘要】：目的探讨慢性阻塞性肺疾病(COPD)患者及正常吸烟者呼出气冷凝液(EBC)中白介素9(IL-9)水平的变化。方法选取2006年9—12月北京大学第一医院诊治的COPD稳定期患者20例,COPD急性加重期患者9例,健康非吸烟人群14例,健康吸烟者10例。收集EBC前使用Jaeger肺功能仪测定吸入支气管扩张剂后第1秒用力呼气末容积占预计值的百分比(FEV1%)和第1秒用力呼气末容积/用力肺活量(FEV1/FVC),采用双抗夹心酶联免疫吸附法检测各组EBC中IL-9水平。应用SPSS统计学软件进行数据分析。结果 4组FEV1%、FEV1/FVC比较,差异均有统计学意义(P0.05);其中健康吸烟组、COPD稳定期组、COPD急性加重期组FEV1%较健康非吸烟组降低,COPD稳定期组、COPD急性加重期组较健康吸烟组降低,COPD急性加重期组较COPD稳定期组降低(P0.05);COPD稳定期组、COPD急性加重期组FEV1/FVC较健康非吸烟组和健康吸烟组降低,COPD急性加重期组较COPD稳定期组降低(P0.05)。4组EBC中IL-9水平比较,差异无统计学意义(P0.05)。COPD稳定期及急性加重期患者EBC中IL-9水平与年龄、累计吸烟量、FEV1%、FEV1/FVC均无直线相关关系(P0.05)。结论未能发现不同组间EBC中IL-9水平的差异及与吸烟及COPD患者气道炎性反应间的关系。EBC中IL-9水平在COPD气道炎症中的作用有待进一步研究。
[Abstract]:Objective to investigate the changes of interleukin 9 (IL-9) in (EBC) of (COPD) patients and normal smokers. Methods from September to December 2006, 20 stable COPD patients, 14 healthy non-smokers and 10 healthy smokers were selected. Forced end-expiratory volume (FEV1%) and forced expiratory volume / forced vital capacity (FEV1/FVC) were measured by Jaeger pulmonary function analyzer at 1 second after inhalation of bronchiectasis (FEV1%) and 1 second forced expiratory volume / forced vital capacity (FEV1/FVC) before EBC. Double antibody sandwich enzyme-linked immunosorbent assay (Elisa) was used. The level of IL-9 in EBC of each group was detected by the attached method. SPSS statistical software was used to analyze the data. Results four groups of FEV1%,FEV1/FVC were compared, The difference was statistically significant (P0.05), in which the FEV1% in the healthy smoking group was stable than that in the healthy non-smoking group during the acute exacerbation period, and the acute exacerbation period group was more stable than the healthy smoking group in the acute exacerbation phase group. The level of IL-9 in FEV1/FVC in the stable phase group was lower than that in the non-smoking group and the healthy smoking group (P0.05), and the level of IL-9 in the EBC of the stable phase group was lower than that of the stable phase group (P0.05), and the level of IL-9 in the acute exacerbation group was lower than that in the non-smoking group and the healthy smoking group (P0.05). There was no significant difference (P0.05). There was no linear correlation between IL-9 level and age in EBC in stable and acute exacerbation stage of COPD, and there was no linear correlation between FEV1 and FEV1 / FVC in cumulative smoking volume (P0.05). Conclusion it is impossible to find the difference of IL-9 level in EBC and the relationship between IL-9 level and airway inflammation in patients with COPD and smoking. The role of IL-9 in COPD airway inflammation needs further study.
【作者单位】：北京大学第一医院呼吸内科;
【分类号】：R563.9

【参考文献】